Abbott Laboratories (NYSE: ABT) made headlines this year after closing a $21 billion cash deal to acquire Exact Sciences, a company focused on cancer diagnostics.

The acquisition targets one of Abbott’s slower-growing business units and signals a strategic push to strengthen its diagnostic capabilities in an increasingly competitive healthcare market.

Abbott also leads the continuous glucose monitoring space through its FreeStyle Libre franchise, giving it a meaningful foothold in one of medical technology’s fastest-expanding categories.

Despite a stretch of mediocre financial results and lingering legal and regulatory headaches, the company’s dividend growth streak remains intact, and analysts see little reason to expect that to change anytime soon.

AbbVie (NYSE: ABBV), which was carved out of Abbott as a standalone public company in 2013, has built a compelling track record of its own since then, outperforming the broader market across that span.

The pharmaceutical company’s two flagship immunology drugs, Skyrizi and Rinvoq, have consistently exceeded expectations and face no U.S. patent expiration until at least 2033.

That long runway gives AbbVie unusual earnings visibility for a large-cap drugmaker, along with time to develop new medicines that could sustain growth well beyond the current decade.

AbbVie has demonstrated an ability to navigate patent cliffs without sacrificing dividend momentum, and the company has now raised its payout for 64 consecutive years when counting the time it operated under Abbott’s umbrella.

Coca-Cola (NYSE: KO) rounds out the group with a similarly long dividend streak of 64 consecutive years, a figure that places it among the most consistent income generators in the entire equity market.

The beverage giant has continued to deliver stability and a reliable income program even as consumers globally have faced persistent cost-of-living pressures and an uncertain macroeconomic backdrop.

All three companies belong to the Dividend Kings, a designation reserved for corporations that have raised their dividends for at least 50 straight years, an elite threshold that fewer than a handful of businesses ever reach.

What separates these three from the broader Dividend Kings universe is a combination of operational depth, market leadership, and the kind of structural advantages that tend to compound investor returns over very long holding periods.